Abbott Laboratories (NYSE:ABT) Issues FY 2026 Earnings Guidance

Abbott Laboratories (NYSE:ABT) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 5.380-5.580 for the period, compared to the consensus EPS estimate of 5.550. The company issued revenue guidance of -. Abbott Laboratories also updated its Q2 2026 guidance to 1.250-1.310 EPS.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Leerink Partners lowered their price target on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a report on Friday, January 30th. Raymond James Financial decreased their price objective on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Argus decreased their price objective on shares of Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Daiwa Securities Group decreased their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Finally, Weiss Ratings downgraded shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $134.58.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $101.55 on Thursday. The company’s 50-day moving average price is $108.45 and its 200-day moving average price is $119.18. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The company has a market cap of $176.86 billion, a P/E ratio of 27.30, a P/E/G ratio of 1.61 and a beta of 0.79. Abbott Laboratories has a twelve month low of $99.05 and a twelve month high of $139.06.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, hitting the consensus estimate of $1.15. The firm had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Insider Transactions at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the sale, the senior vice president owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 3,055 shares of company stock valued at $353,097. Company insiders own 0.46% of the company’s stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Q1 revenue and business strength — Abbott marginally beat consensus on revenue and saw strength in cancer diagnostics and medical devices, which supported the quarter. Abbott first-quarter results beat
• Positive Sentiment: Exact Sciences acquisition — Abbott completed the Exact Sciences deal, positioning the company as a leader in oncology diagnostics and targeting faster growth in that market (guidance incorporates the acquisition and its ~$0.20 EPS dilution). Abbott Reports First-Quarter 2026 Results; Updates Guidance
• Positive Sentiment: Insider buying — Company insiders added roughly $3.10M of ABT stock, a signal some investors view as management confidence in the shares. Insiders Added Stock
• Neutral Sentiment: EPS in line — Adjusted EPS of $1.15 matched consensus, so the quarter was not a surprise on the bottom line; margin/ROE metrics remain solid. Press Release
• Neutral Sentiment: Market narrative — Some commentators label ABT an oversold blue?chip opportunity, which could attract value-oriented buyers if the guidance impact proves temporary. Is Abbott the Best Oversold Blue Chip?
• Negative Sentiment: FY 2026 guidance slightly below consensus — Abbott set FY adjusted EPS at $5.38–$5.58 versus a consensus ~$5.55, signaling marginally lower full?year expectations after factoring in the acquisition. Guidance Update
• Negative Sentiment: Q2 guidance miss — Q2 EPS guidance of $1.25–$1.31 came below the Street (~$1.34), a primary driver of the intraday downside as it suggests near?term growth headwinds. Q2 Guidance
• Negative Sentiment: Segment headwinds & market skepticism — Analysts and commentators point to Nutrition weakness and say management will need to provide reasons on the call to push the stock higher, adding short?term uncertainty. Will Robust Medical Business Performance Fuel ABT’s Q1?

Institutional Investors Weigh In On Abbott Laboratories

Hedge funds and other institutional investors have recently bought and sold shares of the company. Brighton Jones LLC increased its position in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Pinnacle Financial Partners Inc. increased its position in Abbott Laboratories by 21.0% during the third quarter. Pinnacle Financial Partners Inc. now owns 122,698 shares of the healthcare product maker’s stock worth $16,434,000 after purchasing an additional 21,301 shares during the last quarter. Sivia Capital Partners LLC increased its position in Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares during the last quarter. United Bank increased its position in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after acquiring an additional 2,001 shares during the last quarter. Finally, Pacific Excel Wealth Advisors Inc. acquired a new stake in shares of Abbott Laboratories during the fourth quarter valued at about $256,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.